CD274 and non-small cell lung carcinoma: Immunotherapy biomarkers, including elevated PD-L1 and TMB-high, were most common in NSCLC (PD-L1 ≥1% in 63%, ≥10% in 43%, and TMB-high in 17% among 53 samples), head and neck cancer (PD-L1 ≥1% in 100%, ≥10% in 77% among 14 samples), and in urothelial bladder cancer (PD-L1 ≥1% in 88% and TMB-high in 33% among 33 samples).